Cover Image
市場調查報告書

輕度認知障礙 : 開發平台分析

Mild Cognitive Impairment - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 253633
出版日期 內容資訊 英文 111 Pages
訂單完成後即時交付
價格
Back to Top
輕度認知障礙 : 開發平台分析 Mild Cognitive Impairment - Pipeline Review, H2 2016
出版日期: 2016年09月30日 內容資訊: 英文 111 Pages
簡介

所謂輕度認知障礙(MCI)是指隨著年齡認知能力下降,較更嚴重的癡呆症輕的中度認知障礙。主要的症狀有憂鬱症和過敏症·攻擊性、焦慮症、無感情(沒精神)等。易罹病素質有糖尿病及高血壓、憂鬱症、吸煙、膽固醇上升等。

本報告提供全球各國治療輕度認知障礙所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

輕度認知障礙概要

治療藥的開發

  • 輕度認知障礙開發中產品:概要
  • 輕度認知障礙開發中產品:比較分析

各企業開發中的輕度認知障礙治療藥

大學/研究機關研究中的輕度認知障礙治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

輕度認知障礙治療藥:開發中的產品一覽(各企業)

輕度認知障礙治療藥:研究中的產品一覽(大學/研究機關別)

輕度認知障礙開發治療藥的企業

  • Actinogen Limited
  • Avraham Pharmaceuticals Ltd.
  • Boehringer Ingelheim GmbH
  • CereSpir Incorporated
  • D-Pharm Ltd.
  • Eisai
  • Eli Lilly and Company
  • Octapharma AG
  • Sage Therapeutics
  • Sanofi
  • Suven Life Sciences Ltd.

輕度認知障礙:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • BAN-2401
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • BCA-909
  • CSP-1103
  • DAOI-B
  • DP-NDD
  • 人類免疫球蛋白
  • 胰島素注射液
  • ladostigil tartrate
  • levetiracetam
  • LY-3002813
  • SAGE-547
  • SAR-228810
  • 中樞神經系統(CNS)疾病尼古丁性乙醯膽鹼受體α4·β2抑制用小分子
  • SUVN-501
  • SUVN-502
  • SUVN-507
  • SUVN-512
  • SUVN-976
  • SUVND-4010
  • tropisetron hydrochloride
  • UE-2343

輕度認知障礙治療藥:開發中產品的最新趨勢

輕度認知障礙治療藥:開發暫停的產品

輕度認知障礙治療藥:開發中止的產品

輕度認知障礙相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8518IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Pipeline Review, H2 2016, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape.

Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mild Cognitive Impairment - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 7, 8, 1, 11 and 1 respectively for Similarly, the Universities portfolio in Phase II and Discovery stages comprises 2 and 1 molecules, respectively for Mild Cognitive Impairment.

Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Mild Cognitive Impairment (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Mild Cognitive Impairment (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Mild Cognitive Impairment Overview
  • Therapeutics Development
    • Pipeline Products for Mild Cognitive Impairment - Overview
    • Pipeline Products for Mild Cognitive Impairment - Comparative Analysis
  • Mild Cognitive Impairment - Therapeutics under Development by Companies
  • Mild Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes
  • Mild Cognitive Impairment - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Mild Cognitive Impairment - Products under Development by Companies
  • Mild Cognitive Impairment - Products under Investigation by Universities/Institutes
  • Mild Cognitive Impairment - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • AgeneBio Inc.
    • Avraham Pharmaceuticals Ltd.
    • CereSpir Incorporated
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • Ensol Biosciences Inc.
    • Genzyme Corporation
    • IntelGenx Corp.
    • Krenitsky Pharmaceuticals Inc.
    • Nanotherapeutics, Inc.
    • Neuron Biopharma SA
    • Octapharma AG
    • Sage Therapeutics, Inc.
    • Suven Life Sciences Ltd.
    • Takeda Pharmaceutical Company Limited
    • Therapix Biosciences Ltd.
  • Mild Cognitive Impairment - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ABT-957 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAN-2401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSP-1103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSTI-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DAOI-B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dronabinol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KP-544 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ladostigil tartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levetiracetam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-2599666 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3002813 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3303560 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • montelukast sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Moriah-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPS-0158 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPS-0163 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NST-0037 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NST-0076 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NST-0078 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NTC-942 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides to Agonize Insulin Receptor for Mild Cognitive Impairment and Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pioglitazone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sargramostim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sepranolone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize GABRA5 Receptor for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVN-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVN-502 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVN-507 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVN-512 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-071 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tropisetron hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Mild Cognitive Impairment - Dormant Projects
  • Mild Cognitive Impairment - Discontinued Products
  • Mild Cognitive Impairment - Product Development Milestones
    • Featured News & Press Releases
      • Aug 22, 2016: IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain
      • Jul 13, 2016: IntelGenx to Initiate Phase 1 Trial of Montelukast
      • Jul 28, 2015: Avraham Pharmaceuticals Announces Successful Second Interim Results in Phase 2b Study of Ladostigil for the Treatment of Mild Cognitive Impairment
      • Jul 14, 2015: CereSpir Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
      • Jul 01, 2015: CereSpir Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
      • Jul 08, 2014: Avraham Pharmaceuticals Announces Successful Interim Results in Phase 2b Study of Ladostigil for the Treatment of MCI
      • Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON
      • May 17, 2012: Avraham Initiates Phase II Ladostigil Study For Treatment Of Mild Cognitive Impairment
      • Apr 14, 2010: Alzheimer Drug Co Avraham Pharmaceuticals Raises $9m
      • Jul 27, 2009: Suven Presented Positive Phase-I Clinical Data Of SUVN-502 For Alzheimer's Disease At ICAD 2009, Vienna, Austria.
      • Apr 09, 2009: Suven Completes Phase I Clinical Trials Multiple Ascending Dose Of SUVN-502 In Switzerland
      • Oct 13, 2008: Suven Announces That SUVN-502 Data Is Being Presented At 16th BioPartnering In London
      • Sep 29, 2008: Suven Completes Phase-I Clinical Trials Single Ascending Dose Of Suvn-502 In Switzerland
      • Sep 25, 2008: Suven Life Sciences Ltd. Announces DCGI Nod To Conduct Phase-I Clinical Trials Of Suvn-502 For Alzheimer'S Disease
      • Aug 04, 2008: Suven Life Sciences Presents Positive Preclinical Data for Suvn-502 at Alzheimer'S Conference, Chicago and Drug Discovery Conference, Boston
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Mild Cognitive Impairment, H2 2016
  • Number of Products under Development for Mild Cognitive Impairment - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Mild Cognitive Impairment - Pipeline by AbbVie Inc, H2 2016
  • Mild Cognitive Impairment - Pipeline by AgeneBio Inc., H2 2016
  • Mild Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd., H2 2016
  • Mild Cognitive Impairment - Pipeline by CereSpir Incorporated, H2 2016
  • Mild Cognitive Impairment - Pipeline by Eisai Co., Ltd., H2 2016
  • Mild Cognitive Impairment - Pipeline by Eli Lilly and Company, H2 2016
  • Mild Cognitive Impairment - Pipeline by Ensol Biosciences Inc., H2 2016
  • Mild Cognitive Impairment - Pipeline by Genzyme Corporation, H2 2016
  • Mild Cognitive Impairment - Pipeline by IntelGenx Corp., H2 2016
  • Mild Cognitive Impairment - Pipeline by Krenitsky Pharmaceuticals Inc., H2 2016
  • Mild Cognitive Impairment - Pipeline by Nanotherapeutics, Inc., H2 2016
  • Mild Cognitive Impairment - Pipeline by Neuron Biopharma SA, H2 2016
  • Mild Cognitive Impairment - Pipeline by Octapharma AG, H2 2016
  • Mild Cognitive Impairment - Pipeline by Sage Therapeutics, Inc., H2 2016
  • Mild Cognitive Impairment - Pipeline by Suven Life Sciences Ltd., H2 2016
  • Mild Cognitive Impairment - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Mild Cognitive Impairment - Pipeline by Therapix Biosciences Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Mild Cognitive Impairment - Dormant Projects, H2 2016
  • Mild Cognitive Impairment - Dormant Projects (Contd..1), H2 2016
  • Mild Cognitive Impairment - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Mild Cognitive Impairment, H2 2016
  • Number of Products under Development for Mild Cognitive Impairment - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top